Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25042050 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Karla MacDonald-Ramos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Silymarin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Silymarin has ameliorated obesity, type 2 diabetes (T2DM), and insulin resistance (IR) in combination with standard therapy, diet, or exercise in recent studies. Obesity and IR are the main risk factors for developing T2DM and other metabolic disorders. Today, there is a need for new strategies to target IR in patients with these metabolic diseases. In the present longitudinal study, a group of non-diabetic insulin-resistant women with type 1 and type 2 obesity were given silymarin for 12 weeks, with no change in habitual diet and physical activity. We used the Homeostatic Model Assessment for Insulin Resistance Index (HOMA-IR) to determine IR at baseline and after silymarin treatment (t = 12 weeks). We obtained five timepoint oral glucose tolerance tests, and other biochemical and clinical parameters were analyzed before and after treatment. Treatment with silymarin alone significantly reduced mean fasting plasma glucose (FPG) and HOMA-IR levels at 12 weeks compared to baseline values (p < 0.05). Mean fasting plasma insulin (FPI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (Tg), indirect bilirubin, and C-reactive protein (CRP) levels decreased compared to baseline values, although changes were non-significant. The overall results suggest that silymarin may offer a therapeutic alternative to improve IR in non-diabetic individuals with obesity. Further clinical trials are needed in this type of patient to strengthen the results of this study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
- Facultad de Química, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
- Servicio de Oncología, Hospital General de México Dr. Eduardo Liceaga, Ciudad de México 06720, Mexico.
ORCID-Profile: Karla MacDonald-Ramos, Adriana Monroy
Zitieren
APA
MacDonald-Ramos, K., Monroy, A., Bobadilla-Bravo, M., & Cerbón, M. (2024). Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25042050
Vancouver
MacDonald-Ramos K, Monroy A, Bobadilla-Bravo M, Cerbón M. Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25042050
BibTeX
@article{MacDonaldRamos2024,
author = {MacDonald-Ramos, Karla and Monroy, Adriana and Bobadilla-Bravo, Mariana and Cerbón, Marco},
title = {Silymarin Reduced Insulin Resistance in Non-Diabetic Women with Obesity},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25042050}
}
EUVIMED